Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (8005)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Dec 7, 2016 (publication date) through Apr 24, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Schaefer EAK, Meixiong J, Mark C, Deik A, Motola DL, Fusco D, Yang A, Brisac C, Salloum S, Lin W, Clish CB, Peng LF, Chung RT. Apolipoprotein B100 is required for hepatitis C infectivity and Mipomersen inhibits hepatitis C. World J Gastroenterol 2016; 22(45): 9954-9965 [PMID: 28018102 DOI: 10.3748/wjg.v22.i45.9954] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v22/i45/9954.htm |
| Number | Citing Articles |
| 1 |
Gilmar de Souza Lacerda, Thalia Medeiros, Natalia Fonseca do Rosário, Regina Helena Saramago Peralta, Mauro Jorge Cabral-Castro, Eliane Bordalo Cathalá Esberard, Thaís Guaraná de Andrade, Analúcia Rampazzo Xavier, Andrea Alice Silva. Exploring lipid and apolipoprotein levels in chronic hepatitis C patients according to their response to antiviral treatment. Clinical Biochemistry 2018; 60: 17 doi: 10.1016/j.clinbiochem.2018.07.007
|
| 2 |
Matteo Pirro, Vanessa Bianconi, Daniela Francisci, Elisabetta Schiaroli, Francesco Bagaglia, Amirhossein Sahebkar, Franco Baldelli. Hepatitis C virus and proprotein convertase subtilisin/kexin type 9: a detrimental interaction to increase viral infectivity and disrupt lipid metabolism. Journal of Cellular and Molecular Medicine 2017; 21(12): 3150 doi: 10.1111/jcmm.13273
|
| 3 |
Imran Shahid, Qaiser Jabeen. Hepatitis C Virus-Host Interactions and Therapeutics: Current Insights and Future Perspectives. 2023; : 290 doi: 10.2174/9789815123432123010013
|
| 4 |
Sumitra Shankar, Ahalya Sreekumar, Deepti Prasad, Ani V. Das, M. Radhakrishna Pillai. Genome editing of oncogenes with ZFNs and TALENs: caveats in nuclease design. Cancer Cell International 2018; 18(1) doi: 10.1186/s12935-018-0666-0
|
| 5 |
Emilie Crouchet, Thomas F. Baumert, Catherine Schuster. Hepatitis C virus–apolipoprotein interactions: molecular mechanisms and clinical impact. Expert Review of Proteomics 2017; 14(7): 593 doi: 10.1080/14789450.2017.1344102
|
| 6 |
Emilie Crouchet, Florian Wrensch, Catherine Schuster, Mirjam B. Zeisel, Thomas F. Baumert. Host-targeting therapies for hepatitis C virus infection: current developments and future applications. Therapeutic Advances in Gastroenterology 2018; 11: 175628481875948 doi: 10.1177/1756284818759483
|